Can Nattokinase Affect Sleep? 

Sleep disruption affects more than 35% of American adults — and if you take nattokinase for cardiovascular health, wondering whether the enzyme plays any role in your nights is a reasonable question.

The honest answer is: no clinical trial has shown nattokinase directly improves sleep. What nattokinase has shown, consistently, is meaningful blood pressure reduction across multiple human trials — and the relationship between blood pressure control and sleep quality runs deeper than most people realize. There is also a circadian biology angle that makes the timing of your dose worth understanding independently of any sleep outcome.

This article covers the direct evidence, the cardiovascular mechanism behind a plausible indirect effect, and what to make of the reports some users have about noticing sleep changes on nattokinase.

Table of Contents

1. The Direct Evidence: Has Nattokinase Been Tested for Sleep?
2. The Blood Pressure–Sleep Connection
3. Circadian Biology and the Timing of Your Dose
4. What Users Actually Report
5. Practical Guidance for Nattokinase Supplementers
6. BioAbsorb Nattokinase — Cardiovascular Support Around the Clock
7. Frequently Asked Questions
8. Conclusion

1. The Direct Evidence: Has Nattokinase Been Tested for Sleep?

Sleep is not a primary endpoint in nattokinase research. The enzyme has been investigated primarily for its fibrinolytic activity — its ability to dissolve fibrin, lower blood pressure, and modulate cardiovascular risk markers. Sleep appears, when it appears at all, as a secondary or exploratory measure in broader cardiovascular trials. This means the question "does nattokinase affect sleep?" has only a partial answer from controlled human data so far.

The most direct data point comes from a 2025 randomized controlled trial published in the Journal of Stroke and Cerebrovascular Diseases. The study enrolled 120 adults with asymptomatic carotid and intracranial artery narrowing — average age 58 years — and randomly assigned them to 8,000 FU of nattokinase daily or placebo for 6 months. Sleep was assessed as part of a broader cognitive and functional battery. The result: nattokinase produced no statistically significant improvement in sleep outcomes versus placebo. The primary cognitive endpoint (MoCA global score) was also null; an exploratory analysis found a possible benefit in visuospatial function only.

It is important to hold this null finding carefully. The study population was people with arterial narrowing — not a sleep-disorder population, and not a general healthy adult sample. The dose was also 8,000 FU, four times the 2,000 FU level most commonly studied in cardiovascular trials. Whether a lower dose, or a population specifically selected for sleep difficulties alongside cardiovascular risk, would yield different results is genuinely unknown. That question is now being investigated: NCT07229521, sponsored by Taipei Medical University, is enrolling 70–80 adults with metabolic syndrome and co-existing sleep disorders into a 12-week crossover trial at 6,000 FU daily, with sleep quality questionnaires as a primary outcome measure. For a full background on how this enzyme works, see the complete guide to nattokinase.

2. The Blood Pressure–Sleep Connection

Even without direct sleep evidence, there is a scientifically coherent mechanism through which nattokinase could benefit people whose sleep is disrupted by cardiovascular factors. The connection runs through blood pressure. Elevated blood pressure is both a cause and a consequence of disrupted sleep, and nattokinase has the most consistent evidence base in this area of all its studied effects. Understanding the two-way relationship helps explain why a supplement with no direct sleep data is still worth discussing in a sleep context.

The landmark clinical trial on nattokinase and blood pressure is the 2008 RCT by Kim and colleagues. 73 participants with prehypertension or stage 1 hypertension received 2,000 FU of nattokinase or placebo for 8 weeks; the nattokinase group showed a net reduction of 5.55 mmHg in systolic and 2.84 mmHg in diastolic blood pressure. A subsequent North American randomized controlled trial across 74 participants on a Western diet — the first such trial conducted outside Asia — confirmed a statistically significant diastolic blood pressure reduction at 8 weeks (P < 0.04). The 2023 pooled analysis of 6 randomized controlled trials with 546 total participants confirmed consistent, significant reductions in both systolic (−3.45 mmHg) and diastolic (−2.32 mmHg) pressure across the evidence base. For a full breakdown of the blood pressure trial data, see the dedicated article on nattokinase and blood pressure research.

The sleep side of this equation is equally well established. Analysis of 12,166 adults from the NHANES database found that self-reported trouble sleeping was associated with 45% higher odds of hypertension (OR = 1.45), and short sleep duration under 7 hours carried 20% higher odds (OR = 1.20). The Nurses' Health Study 2 — tracking over 66,000 women for years — confirmed that difficulty falling or staying asleep was independently associated with elevated hypertension risk. The relationship is bidirectional: elevated blood pressure disrupts sleep architecture by increasing nocturnal arousal, and fragmented sleep raises blood pressure by activating the sympathetic nervous system. For someone sitting in mildly elevated blood pressure territory, nattokinase's consistent 3–5 mmHg systolic reductions may create downstream improvements in sleep — not by acting on sleep directly, but by pulling on a thread the cardiovascular and sleep systems share.

3. Circadian Biology and the Timing of Your Dose

There is a separate angle on nattokinase and sleep that has nothing to do with sleep quality directly, but everything to do with when you take your dose. It comes from circadian biology — specifically, the body's daily rhythm in clotting and fibrinolytic activity. Understanding it helps you make a more informed decision about dose timing even if you have no sleep concerns at all.

PAI-1, the enzyme that nattokinase specifically inhibits, follows a robust daily rhythm. Research published in Blood by Scheer and Shea demonstrated that PAI-1 peaks at approximately 6:30 AM, driven by the body's internal circadian clock rather than sleep or waking behaviour. This morning peak was found to be 8 times larger than changes in PAI-1 caused by behavioural stressors such as exercise or posture change. High PAI-1 suppresses the body's natural fibrinolytic activity — its ability to dissolve clots — and this suppression coincides precisely with the window when cardiovascular events peak. A 2021 systematic review in Thrombosis Research confirmed that this morning reduction in fibrinolytic activity is more pronounced in cardiovascular patients than in healthy individuals, increasing clotting risk at exactly the time blood pressure also tends to surge.

The implication for nattokinase timing: if PAI-1 peaks around 6:30 AM and nattokinase's fibrinolytic effects persist for several hours after a single dose, then evening administration positions the enzyme's activity window against the high-risk morning period. This rationale is biologically coherent — and it is why some practitioners suggest evening dosing for cardiovascular protection purposes. However, it has not been formally tested in a clinical trial comparing morning versus evening dosing outcomes, and how nattokinase works at the enzyme level is covered in detail in the dedicated mechanistic article. The timing question is worth returning to as trial data accumulates.

4. What Users Actually Report

No peer-reviewed study has systematically surveyed user-reported sleep effects of nattokinase. What exists is a body of consumer accounts from supplement review platforms that reveals a mixed and sometimes contradictory pattern — one that is useful to understand, even if it carries no clinical weight.

Among user reviews collected on WebMD, accounts at both ends of the spectrum appear. Some individuals who take nattokinase before bed report waking earlier than usual — after 5 to 6 hours — feeling unexpectedly alert in a way that prevents returning to sleep. Others describe improved sleep continuity, attributing the change to resolved circulation issues that had previously fragmented their nights: cold extremities, nocturnal urination linked to vascular changes, or cardiovascular discomfort at rest. A third group reports no sleep-related change at all. These patterns are internally consistent with what the science would predict. People whose sleep disruption has a cardiovascular root cause — mild hypertension, poor peripheral circulation, nocturnal blood pressure surges — may experience indirect improvements as nattokinase addresses those underlying factors. People without cardiovascular drivers of their sleep disruption are unlikely to notice any sleep effect one way or the other.

The 2025 RCT remains the most reliable reference point, and it found no population-level sleep improvement at 8,000 FU in a cardiovascular population over 6 months. The user reports are real, but they reflect individual variation rather than a predictable effect. What they do usefully signal is the importance of tracking when you take your dose — a pattern the next section addresses.

5. Practical Guidance for Nattokinase Supplementers

If you take nattokinase and want to think clearly about its relationship to your sleep, here is what the evidence reasonably supports:

• The standard dose is 100 mg (2,000 FU) daily on an empty stomach. This is the dose most consistently studied in blood pressure trials and the formulation most nattokinase products use. Taking it on an empty stomach maximises enzyme delivery to the small intestine. The nattokinase dosage guide covers the clinical dose range in full, including higher-dose protocols used in more recent cardiovascular research.
• Morning versus evening timing has not been studied in a clinical trial. The circadian argument for evening dosing — positioning fibrinolytic activity against the 6:30 AM PAI-1 peak — is biologically coherent but unproven by direct head-to-head comparison. Evening dosing is not contraindicated; it simply lacks formal comparative evidence.
• If you notice earlier-than-usual waking after starting nattokinase, consider shifting your dose earlier. The accounts of early-morning arousal come primarily from people dosing at bedtime. Moving the dose to late afternoon or early evening — 4 to 6 hours before intended sleep — may resolve this without reducing cardiovascular benefit, since nattokinase's fibrinolytic activity persists for hours after ingestion.
• Sleep disruption is not a documented adverse event in clinical trials. The 2025 RCT at 8,000 FU daily — four times the standard dose — did not identify sleep disturbance as a treatment-related adverse event. If you experience persistent, significant sleep disruption after starting nattokinase, consult a healthcare provider; the cause is likely unrelated to the supplement. For a full reference on reported nattokinase side effects, see the dedicated nattokinase side effects article.

For anyone taking blood pressure medications or anticoagulants — a group for whom both sleep and nattokinase warrant physician discussion — see the natural blood thinner and drug interaction overview before making any dosing decisions.

BioAbsorb Nattokinase — Cardiovascular Support Around the Clock

BioAbsorb Nutraceuticals formulates its Nattokinase Enzyme at 100 mg per capsule, standardized to 2,000 FU of fibrinolytic activity — the dosing level used in the clinical trials showing consistent blood pressure reductions. Each capsule delivers the enzyme activity that research has validated for cardiovascular effects, without the guesswork of unstandardized products.

Delivery technology matters here. BioAbsorb uses DRcaps — delayed-release vegetarian capsules engineered to protect nattokinase from stomach acid, ensuring the enzyme reaches the small intestine intact where absorption occurs. Standard capsules risk degrading the enzyme before it can work; DRcaps eliminates this without the phthalates and plasticizers found in many enteric-coated alternatives. The product is also intentionally free of Vitamin K2 — a deliberate formulation choice that allows for long-term dosing without the cardiovascular caveats associated with K2 accumulation in people who are already supplementing this nutrient.

Every batch is third-party tested for nattokinase activity (≥2,000 FU per capsule verified), heavy metals, gluten, and microbial contaminants — with certificates of analysis available on request. The formulation is non-GMO, 100% vegetarian, and free of all major allergens: gluten, nuts, eggs, dairy, fish, and shellfish. Manufactured in a Canadian GMP-certified facility. At $49.87 for 180 capsules — a 6-month supply at 1 capsule per day — the cost is approximately $0.28 per day, which compares favourably with competitor 60-cap products at similar price points.

Frequently Asked Questions

Can nattokinase cause insomnia?

No clinical trial has identified insomnia as an adverse effect of nattokinase at standard doses. A 2025 RCT administering 8,000 FU per day for 6 months did not flag sleep disturbance as a treatment-related adverse event. If you notice difficulty sleeping after starting nattokinase, the most likely explanation is dose timing rather than the enzyme itself — try shifting from bedtime to late afternoon and monitor whether the pattern changes over 1 to 2 weeks.

Should I take nattokinase at night for better sleep?

Evening dosing is biologically plausible as a cardiovascular timing strategy: PAI-1, nattokinase's primary enzyme target, peaks at approximately 6:30 AM, and evening administration would position fibrinolytic activity against that high-risk morning window. However, no clinical trial has directly compared morning versus evening dosing for either cardiovascular or sleep outcomes. Taking nattokinase in the evening is not contraindicated — but if you find that bedtime dosing disrupts your sleep onset or causes early-morning waking, shifting to 4 to 6 hours before bed is a reasonable adjustment.

Is nattokinase useful for sleep apnea?

No clinical evidence supports nattokinase as a treatment for sleep apnea — sleep apnea involves airway obstruction, which is outside nattokinase's mechanism of action. That said, nattokinase's well-documented blood pressure reductions may offer complementary cardiovascular support for people managing both sleep apnea and hypertension, since uncontrolled blood pressure worsens cardiovascular outcomes in sleep apnea patients. Sleep apnea itself requires medical evaluation; established interventions like CPAP are the appropriate primary treatment.

How long before I notice blood pressure effects from nattokinase?

The most cited clinical evidence — Kim et al. 2008 — ran for 8 weeks and produced statistically significant systolic changes over that period. Blood pressure effects are unlikely to appear within the first few days; the available evidence suggests 4 to 8 weeks of consistent daily supplementation is needed before meaningful changes emerge. Individual variation is real — some participants in trials showed larger responses than others, and baseline blood pressure level is a likely predictor of response magnitude.

Does nattokinase interact with sleep medications?

No known direct pharmacological interaction between nattokinase and standard sleep aids — melatonin, benzodiazepines, or Z-drugs — has been documented in clinical literature. The clinically meaningful interaction concern with nattokinase relates to its blood-thinning properties, not sleep specifically: it carries additive risk when combined with anticoagulants (warfarin, DOACs) or antiplatelet agents. If you take prescription blood thinners for any reason — including cardiovascular conditions that may be affecting your sleep — consult a physician before starting nattokinase. The natural blood thinner and drug interactions guide covers the full interaction picture.

Is there a clinical trial specifically studying nattokinase for sleep?

Yes — as of mid-2026, NCT07229521, sponsored by Taipei Medical University, is actively recruiting 70 to 80 adults with metabolic syndrome and co-existing sleep disorders for a 12-week double-blind crossover trial using 6,000 FU of nattokinase daily. Sleep quality questionnaires are among the primary outcome measures, alongside cardiovascular risk markers, gut microbiota changes, and cognitive function. This is the first trial with sleep as a central endpoint, and it will provide substantially more direct evidence than any data currently available.

Conclusion

Nattokinase has not been shown to directly improve sleep — the one RCT that measured sleep as an outcome in 120 adults found no significant effect at even 8,000 FU daily. The more credible connection runs through blood pressure: consistent clinical evidence shows nattokinase reducing systolic pressure by 3 to 5 mmHg across populations, and that kind of reduction may benefit people whose sleep is disrupted by cardiovascular factors. A dedicated sleep trial is now under way and will produce more direct answers within the next 1 to 2 years. In the meantime, for cardiovascular support that works through the night and into the morning hours when cardiovascular risk peaks, explore BioAbsorb Nattokinase Enzyme.

Research References

1. Effects of Nattokinase on Blood Pressure: A Randomized, Controlled Trial. Hypertension Research (2008). Landmark 8-week RCT in 73 adults with prehypertension or stage 1 hypertension; nattokinase at 2,000 FU daily produced net reductions of 5.55 mmHg systolic and 2.84 mmHg diastolic versus placebo.
2. Nattokinase Supplementation and Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Reviews in Cardiovascular Medicine, Vol. 24(8) (2023). Pooled analysis of 6 RCTs with 546 participants confirming significant reductions in both systolic (−3.45 mmHg) and diastolic (−2.32 mmHg) blood pressure with nattokinase supplementation versus placebo.
3. Consumption of Nattokinase Is Associated With Reduced Blood Pressure and Von Willebrand Factor: A Randomized, Double-Blind, Placebo-Controlled, Multicenter North American Clinical Trial. Integrated Blood Pressure Control, Vol. 9 (2016). First RCT of nattokinase in a North American population on Western diet; confirmed statistically significant diastolic blood pressure reductions at 8 weeks (P < 0.04).
4. Human Circadian System Causes a Morning Peak in Prothrombotic Plasminogen Activator Inhibitor-1 (PAI-1) Independent of the Sleep/Wake Cycle. Blood, Vol. 123(4) (2014). Demonstrated a robust endogenous circadian rhythm in PAI-1 peaking at ~6:30 AM — 8x larger than changes caused by behavioral stressors — explaining the morning peak in adverse cardiovascular events and providing biological rationale for evening fibrinolytic dosing.
5. Impact of the Circadian Clock on Fibrinolysis and Coagulation in Healthy Individuals and Cardiovascular Patients: A Systematic Review. Thrombosis Research, Vol. 207 (2021). Confirmed that morning reductions in fibrinolytic activity are more pronounced in cardiovascular patients than healthy individuals, increasing morning clotting risk at the same time blood pressure surges.
6. Nattokinase Supplementation for Cognitive Enhancement in Asymptomatic Intracranial/Carotid Stenosis: A Randomized Controlled Trial. Journal of Stroke and Cerebrovascular Diseases, Vol. 35(1) (2026). RCT of 120 adults at 8,000 FU nattokinase daily for 6 months; found no significant improvement in sleep or global cognitive function versus placebo, with exploratory benefit in visuospatial function only — the primary controlled evidence on nattokinase and sleep.
7. Sleeping Difficulties, Sleep Duration, and Risk of Hypertension in Women. Hypertension, Vol. 80 (2023). Nurses' Health Study 2 analysis of 66,122 participants finding sleep difficulties and short sleep duration independently associated with increased hypertension risk; estimates 45% of US adults have hypertension.
8. Relationship Between Sleep and Hypertension: Findings From the NHANES (2007–2014). International Journal of Environmental Research and Public Health, Vol. 18 (2021). Analysis of 12,166 adults confirming short sleep duration (OR = 1.20), trouble sleeping (OR = 1.45), and sleep disorders (OR = 1.33) as independent predictors of hypertension risk.

About the Author

David Kimbell is a health writer, digital entrepreneur and former aerospace engineer, based in Ottawa, Canada. He loves translating complex science into clear, actionable guidance for consumers seeking evidence-based solutions.

---

Important Disclaimers

Medical Disclaimer: This article provides educational information only and is not intended as medical advice. Always consult with a qualified healthcare provider before starting any new supplement, especially if you have existing health conditions, take medications, or are pregnant or nursing.

FDA/Health Canada Statement: These statements have not been evaluated by the Food and Drug Administration or Health Canada. This product is not intended to diagnose, treat, cure, or prevent any disease.